Please login or register first to view this content.
Oncology Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi’s sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
NEWS & FEATURES
New Dosing Option Approved for Imfinzi in NSCLC, Bladder Cancer
Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC
Keytruda Approved for Triple-Negative Breast Cancer
Investigational Multiple Myeloma Treatment Gets Orphan Drug Status
Cemiplimab Granted Priority Review for Advanced NSCLC
HER2-Directed Treatment Gets Priority Review for Gastric Cancer
USPSTF Issues Draft Recommendation for CRC Screening
Nivolumab Plus Cabozantinib Under Review for Renal Cell Carcinoma
Osimertinib Gets Priority Review for Early-Stage EGFR-Mutated NSCLC
FDA Grants Full Approval to Venclexta for Acute Myeloid Leukemia
Keytruda Approval Expands Classical Hodgkin Lymphoma Indication
Malignancies May Occur Earlier in Men vs Women After Sarcoidosis Diagnosis
Palbociclib Misses Primary End Point in Early Breast Cancer Trial
Common Cardiovascular Drugs Associated With Reduced Lung Cancer Mortality
Abemaciclib Beneficial for HR+, HER2− Early Breast Cancer
Opdivo Plus Yervoy Approved for Malignant Pleural Mesothelioma
Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
